- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07667231
PENG+LFCN Block vs QIPB for Total Hip Arthroplasty
Comparison Between Quadro-iliac Plane Block (QIPB) and Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve Block for Total Hip Arthroplasty: a Randomized Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Materials and Methods:
This prospective, randomized clinical trial will include patients aged 18-80 years with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled to undergo elective unilateral primary total hip arthroplasty unde spinal anesthesia. Before enrollment, all patients will be informed about the study protocol and written informed consent will be obtained. Patients will be instructed on the use of the Numeric Rating Scale (NRS) for postoperative pain assessment, where 0 represents no pain and 10 represents the worst pain imaginable.
Patients with contraindications to spinal anesthesia, allergy to local anesthetics, coagulopathy, infection at the injection site, chronic opioid use, pre-existing neurological deficits involving the lower extremities, cognitive impairment preventing reliable communication, revision or bilateral hip arthroplasty, and refusal to participate will be excluded from the study.
Patients will be randomly allocated to one of two study groups using a computer-generated randomization sequence (https://www.randomizer.org). Randomization will be performed by a team member not involved in patient management or outcome assessment. Allocation concealment will be achieved using sequentially numbered sealed opaque envelopes, which will be opened immediately before block performance.
Upon arrival in the operating room, standard monitoring including electrocardiography, non-invasive blood pressure measurement, and pulse oximetry will be applied. Following intravenous access and preloading according to institutional practice, spinal anesthesia will be performed at the L3-L4 or L4-L5 intervertebral space using a 25-gauge Quincke spinal needle under aseptic conditions. After confirmation of free cerebrospinal fluid flow, 12-15 mg of 0.5% hyperbaric bupivacaine will be administered intrathecally. Supplemental sedation with intravenous midazolam and/or propofol may be provided when required for patient comfort.
Following successful spinal anesthesia, patients will receive either ultrasound-guided quadro-iliac plane block (QIPB) or ultrasound-guided pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve block according to group allocation. All blocks will be performed by anesthesiologists experienced in regional anesthesia and familiar with both techniques.
All patients will receive the same multimodal postoperative analgesic regimen and standardized postoperative rehabilitation protocol. Postoperative pain scores at rest and during movement will be assessed using the NRS during the first 48 postoperative hours. Opioid consumption, incidence of quadriceps motor block, time to first ambulation, patient satisfaction, postoperative nausea and vomiting, falls, length of hospital stay, block performance time, and block-related complications will also be recorded.
Outcome assessments will be performed by investigators who are unaware of group allocation.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: MUSTAFA KILIN, Consultant Anesthesiologists
- Numéro de téléphone: +905464569218
- E-mail: mustafa.kilin90@gmail.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age between 18 and 80 years
- American Society of Anesthesiologists physical status I-III
- Scheduled for elective unilateral primary total hip arthroplasty
- Surgery planned under spinal anesthesia
- Ability to understand and use the Numeric Rating Scale
- Written informed consent provided
Exclusion Criteria:
- Refusal to participate
- Revision total hip arthroplasty
- Bilateral total hip arthroplasty
- Contraindication to spinal anesthesia
- Contraindication to peripheral nerve block
- Known allergy to local anesthetics or study drugs
- Coagulopathy or anticoagulant use incompatible with neuraxial/regional anesthesia
- Infection at the block injection site
- Pre-existing neurological deficit involving the operative lower extremity
- Peripheral neuropathy
- Chronic opioid use
- Cognitive impairment or inability to communicate reliably
- Severe hepatic or renal failure
- Body mass index >35 kg/m²
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: quadro-iliac plane block (QIPB)
|
Participants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia.
Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.
|
|
Comparateur actif: pericapsular nerve group (PENG) block combined with lateral femoral cutaneous nerve block
|
Participants in the PENG group will undergo an ultrasound-guided pericapsular nerve group (PENG) block after spinal anesthesia.
A total of 20 mL of 0.25% bupivacaine will be administered.
Participants in the LFCN group will undergo an ultrasound-guided lateral femoral cutaneous nerve block after spinal anesthesia.
A total of 10 mL of 0.25% bupivacaine will be administered.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative pain scores
Délai: Postoperative 6, 24, 36, and 48 hours
|
Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain.
Pain scores at rest will be recorded in the post-anesthesia care unit and at postoperative 6, 24, 36, and 48 hours.
Pain scores during movement will be assessed during passive flexion of the operated hip at postoperative 6, 24, 36, and 48 hours.
|
Postoperative 6, 24, 36, and 48 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative opioid consumption
Délai: Postoperative 24 and 48 hours
|
Total postoperative opioid consumption will be recorded and cumulative opioid consumption will be calculated at postoperative 24 and 48 hours.
|
Postoperative 24 and 48 hours
|
|
Incidence of quadriceps motor block
Délai: Postoperative 3, 6, and 24 hours
|
Quadriceps motor block will be assessed using knee extension testing and graded as: 0 = normal strength
|
Postoperative 3, 6, and 24 hours
|
|
Patient satisfaction
Délai: Postoperative 48 hours
|
Patient satisfaction with postoperative analgesia will be assessed using a Likert scale.
|
Postoperative 48 hours
|
|
Postoperative nausea and vomiting (PONV)
Délai: Postoperative 48 hours
|
Incidence of postoperative nausea and vomiting during the first 48 postoperative hours.
|
Postoperative 48 hours
|
|
Falls
Délai: Through postoperative day 2
|
Incidence of falls during the first 48 postoperative hours.
|
Through postoperative day 2
|
|
Length of hospital stay
Délai: Through hospital discharge, up to 30 days
|
Number of days from surgery to hospital discharge.
|
Through hospital discharge, up to 30 days
|
|
Time to first ambulation
Délai: Postoperative day 1
|
Time from the end of surgery to the first successful ambulation.
|
Postoperative day 1
|
|
Block performance time
Délai: Periprocedural
|
Time from ultrasound probe placement to completion of local anesthetic injection.
|
Periprocedural
|
|
Block-related complications
Délai: Through hospital discharge, up to 30 days
|
Hematoma Vascular puncture Local anesthetic systemic toxicity (LAST) Infection at the injection site
|
Through hospital discharge, up to 30 days
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- QİPBvsPENG+LFCN
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .